Recently, the combined medicine composed of amodiaquine tablets + compound sulfadoxine tablets (150mg+ 25mg/500mg) (WHO reference number: MA098) produced by Guilin South Pharma Company Limited, a subsidiary of Fosun Pharma, (“Guilin Pharma”) officially passed the WHO-PQ certification (i.e. Pre-Qualification certification of the World Health Organization). At present, Guilin Pharma is the sole PRC preparation enterprise passing WHO-PQ certification. Starting from December 2015, Guilin Pharma will have 12 varieties (including 11 preparation varieties and 1 API variety) passing PQ certification.

As early as 2005, the artesunate tablet produced by Guilin Pharma passed the WHO-PQ certification. The jointly packaged tablet of amodiaquine + compound sulfadoxine is the 11th finished preparation passing the WHO-PQ certification of Guilin Pharma and also the first product of the SMC (Seasonal Malaria Chemoprevention) series passing the WHO-PQ certification. It has become a good start of Guilin Pharma in the field of malaria prevention products.

Currently, approximately half of the world’s population is confronted with the risk of malaria. Early diagnosis and treatment of malaria can shorten the course of the illness to prevent death and also contributes to reducing malaria transmission. Among the measures for malaria prevention, antimalarial has been used for a long time. The people in the areas of malaria prevalence avoid taking preventive drugs, partly because they are afraid that taking such drug for a long time will cause the plasmodium to form resistance against the drug. The combined medicine composed of amodiaquine tablets + compound sulfadoxine tablets produced by Guilin Pharma can effectively prevent malaria with minimal side effects, e.g. drug resistance of parasite, low immunity, etc., and cost much less than that of malaria treatment. Therefore, it has become one of the best choices for malaria prevention.

This move symbolizes that Guilin Pharma has taken a firm step on the road of building a manufacturing enterprise specialized in antimalarial and expanding and deepening the international market of antimalarial.

Attached: Ten-year review of WHO-PQ certification of Guilin Pharma (2004-2014)

At present, Guilin Pharma has 12 varieties (including 11 preparation varieties and 1 API variety) passing PQ certification. The list of corresponding WHO reference numbers (MA represents ANTIMALARIALS) is shown below:
The 11 preparation products (note: there are 40 finished MA preparations passing PQ certification in the list of WHO) are:
1. * MA044- artesunate tablets (50mg) (21 December 2005) ;
2. * MA045- amodiaquine tablets (150mg, basic group) (30 August 2007);
3. * MA046- combined medicine composed of artesunate tablets (50mg) + amodiaquine tablets (150mg, basic group); trade name: ASUAMOON(30 August 2007, the same date of MA045);
4.* MA051- artesunate for injection (60mg) + 5% sodium bicarbonate injection (1mL:50mg, menstruum) + 0.9% sodium chloride injection (5mL:45mg, diluent) / trade name ARTESUN (5 November 2010)
5.* MA066- artesunate tablets (50mg) + sulfadoxine/pyrimethamine (500mg/25mg) tablets /trade name ARTECOSPE (24 May 2012)
6.* MA083- artesunate-amodiaquine (25mg/67.5mg) bilayer tablets/trade name ARTESUN-PLUS (16 November 2012)
7. * MA084- artesunate-amodiaquine (50mg/135mg) bilayer tablets/ trade name ARTESUN-PLUS (16 November 2012)
8.* MA085- artesunate-amodiaquine (100mg/270mg) bilayer tablets/ trade name ARTESUN-PLUS (16 November 2012)
9.* MA089- artesunate for injection (30mg) + 5% sodium bicarbonate injection (0.5mL:25mg, menstruum) + 0.9% sodium chloride injection (2.5mL:22.5mg, diluent) / trade name ARTESUN (23 May 2013)
10.* MA090- artesunate for injection (120mg) + 5%sodium bicarbonate injection(2mL:100mg, menstruum) + 0.9% sodium chloride injection (10mL:90mg, diluent) / trade name ARTESUN (23 May 2013)
11.- sulfadoxine/pyrimethamine (500mg/25mg) +amodiaquine tablet (150mg, basic group) / trade name SPAQCO (20 October 2014)

2) API variety: artemether API(WHOAPI-181, 27 May 2014).

About Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) was established in 1994. As a leading company in China’s pharmaceutical and healthcare industry, Fosun Pharma was listed on the Shanghai Stock Exchange and on the main board of the Hong Kong Stock Exchange(stock code: 600196-SH, 02196-HK) in August 1998 and October 2012.

Fosun Pharma strategically operates in several key sectors on the value-chain of the pharmaceutical and healthcare industry. Our main business includes pharmaceutical research and development, manufacturing, distribution and retailing, medical devices and diagnostic products as well as healthcare services. The company owns a national-level Technology Center and has a R&D team with international perspective. We had been continuously focusing on innovative research and development in therapeutic areas such as metabolism and alimentary tract, cardiovascular system, central nervous system, anti-tumor as well as anti-infective treatment.

Our commitment is “Innovation for Good Health”. In future, Fosun Pharma will continue to implement its strategy of organic growth with external expansion and integrated business operation. We are dedicated to become a first class enterprise in major global healthcare market. For more information on Fosun Pharma, please visit www.fosunpharma.com.